Oslo, Norway, 19 October 2020 - Targovax ASA (OSE: TRVX), a clinical stage
immuno-oncology company developing oncolytic viruses to target hard-to-treat
solid tumors, today announces that an abstract on the mesothelioma trial has
been accepted and will be presented at the Society for Immunotherapy of Cancer
(SITC) 35th Anniversary Annual Meeting, 9 -14 November 2020.

The abstract presents the 12-month analysis of biomarkers and clinical outcome
from the phase I/II trial in malignant pleural mesothelioma where ONCOS-102 is
added to standard of care chemotherapy (pemetrexed / cisplatin). This analysis
supports the data presented in June.

Abstract  A randomised open-label phase I/II study adding ONCOS-102 to
title     pemetrexed/cisplatin in patients with unresectable malignant pleural
          mesothelioma - 12-month analysis of biomarkers and clinical outcomes
Abstract  361
number
Poster    ePoster available throughout the conference
session

***

About SITC Annual Meeting 2020

The Society for Immunotherapy of Cancer's (SITC) 35th Anniversary Annual Meeting
& Pre-Conference Programs (SITC 2020) will be reimagined as a fully VIRTUAL
experience this year to ensure the health and safety of program attendees and
their patients.

SITC 2020 provides a multidisciplinary educational and interactive environment
focused on improving cancer patient outcomes by incorporating strategies based
on basic and applied cancer immunotherapy.

For further information, please contact:
Renate Birkeli, Investor Relations
Phone: +47 922 61 624
Email: renate.birkeli@targovax.com
Media and IR enquires:
Andreas Tinglum - Corporate Communications (Norway)
Phone: +47 9300 1773
Email: andreas.tinglum@corpcom.no

About Targovax

Activating the patient's immune system to fight cancer

Targovax (OSE:TRVX) is a clinical stage immuno-oncology company developing
oncolytic viruses to target hard-to-treat solid tumors. Targovax's lead product
candidate, ONCOS-102, is a genetically modified oncolytic adenovirus, which has
been engineered to selectively infect cancer cells and activate the immune
system to fight the cancer.

ONCOS-102 is currently being tested in mesothelioma, melanoma and peritoneal
malignancies and has already shown promising clinical results both as
monotherapy and in combination with chemotherapy, and a checkpoint inhibitor.